<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/67B34D05-3A52-4A09-8FF9-F2398D60E246"><gtr:id>67B34D05-3A52-4A09-8FF9-F2398D60E246</gtr:id><gtr:name>University of Surrey</gtr:name><gtr:address><gtr:line1>Registry</gtr:line1><gtr:line2>Stag Hill</gtr:line2><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 7XH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8143BC10-4BF9-4C93-8A0C-DB09DC8F750D"><gtr:id>8143BC10-4BF9-4C93-8A0C-DB09DC8F750D</gtr:id><gtr:name>Technical University Darmstadt</gtr:name><gtr:address><gtr:line1>Karolinenplatz 5</gtr:line1><gtr:line4>Darmstadt</gtr:line4><gtr:line5>D-64289</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:department>School of Medical Sciences</gtr:department><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/67B34D05-3A52-4A09-8FF9-F2398D60E246"><gtr:id>67B34D05-3A52-4A09-8FF9-F2398D60E246</gtr:id><gtr:name>University of Surrey</gtr:name><gtr:address><gtr:line1>Registry</gtr:line1><gtr:line2>Stag Hill</gtr:line2><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 7XH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8143BC10-4BF9-4C93-8A0C-DB09DC8F750D"><gtr:id>8143BC10-4BF9-4C93-8A0C-DB09DC8F750D</gtr:id><gtr:name>Technical University Darmstadt</gtr:name><gtr:address><gtr:line1>Karolinenplatz 5</gtr:line1><gtr:line4>Darmstadt</gtr:line4><gtr:line5>D-64289</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F4CB0FAF-CFEF-4D10-96B4-D6CEB5C89C4C"><gtr:id>F4CB0FAF-CFEF-4D10-96B4-D6CEB5C89C4C</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Porter</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FK010905%2F1"><gtr:id>01ABB28F-5A93-4B88-8C84-5FAF9D004BBC</gtr:id><gtr:title>To benchmark the utility of E06: A half-life extension, single-domain, shark antibody bio-tool, and progress it to a Phase 1 ready candidate clone</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/K010905/1</gtr:grantReference><gtr:abstractText>Scientifically we are developing a &amp;quot;bio-tool&amp;quot; that could be fused to a range of different therapeutic proteins/peptides to extend their serum half-life from hours to weeks, with the potential of greatly increasing their therapeutic potency. It works by hitching a ride on other long-lived proteins in the blood. Commercially, our medium-term goal is to create a Drug Discovery company, based on our unique, single-domain shark antibody (VNAR) platform, which will develop therapeutic agents in-house or in partnership with larger companies. To achieve this, meeting of scientific milestones is key, and in particular confirming non-immunogenicity (not seen by the human immune system &amp;amp; safe for use), and validate the most advanced of our products (E06 VNAR half-life extension bio-tool). Progress towards this goal will also provide a platform for NewCo formation and equity raising, and will deliver an asset capable of securing multiple revenue streams of licensing and partnered income.</gtr:abstractText><gtr:fund><gtr:end>2014-09-09</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2013-02-10</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>435489</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Surrey</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Co-expression of therapeutic proteins with a VNAR half-life extension bio-tool.</gtr:description><gtr:id>21EA7E99-6DCC-48E4-B9EA-8E29A2EE6A8E</gtr:id><gtr:impact>Started formally November 2014</gtr:impact><gtr:outcomeId>546222eb74eb42.65952933-1</gtr:outcomeId><gtr:partnerContribution>Cloning of our half-life extension bio-tool as a fusion with a therapeutic protein, expression and characterisation of the fusion protein in a suitable animal model of disease.</gtr:partnerContribution><gtr:piContribution>Supply of relevant genetic and protein materials suitable for cloning and assay development.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>VNARs as Bio-Processing tools for the production of bi-specific antibodies for use in human therapies</gtr:description><gtr:id>08ECADC3-8313-49C6-99D6-76B00F6E5B47</gtr:id><gtr:impact>No definitive outcomes yet but all the early data looks very promising and we are in the late stage characterisation of our panel of specific binders.</gtr:impact><gtr:outcomeId>56dff0f76af126.86321856-1</gtr:outcomeId><gtr:partnerContribution>They have provided financial support for staff and consumables, materials for the selection process and BIAcore analysis of outputs using their facility in the US.</gtr:partnerContribution><gtr:piContribution>We have been isolating VNAR binders from our synthetic drug libraries that will recognise different formulations of Mercks therapeutic drugs. These VNARs have the potential to be used in bio-processing to aid the manufacture, purification and QC of these drugs at scale.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Darmstadt</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Isolatiuon of VNAR from novel shark species</gtr:description><gtr:id>4A1F0372-15DC-4F2F-A501-AF6B4D5EF363</gtr:id><gtr:impact>VNAR specific binders to a therapeutically relevant target, successful immunisation of a new elasmobranch species, paper in preparation</gtr:impact><gtr:outcomeId>54637d7636b909.71034848-1</gtr:outcomeId><gtr:partnerContribution>Darmstadt have provided expertise using a novel display system for the selection of antigen specific VNAR bimders</gtr:partnerContribution><gtr:piContribution>We have provided expertise in the cloning of antigen specific VNAR libraries from an immunised source</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>3rd UK - China Healthtech Open Innovation Workshop, platform presentation, Guangzhou, China, 17th June, Shark VNAR Biologics</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EDD4F70B-B06D-4A7F-8D78-596C28417B1D</gtr:id><gtr:impact>Two science focussed grant applications were submitted with Chinese and Chinese/US collaborators for funding by the Chinese Government.

Unfortunately the grants were not awarded. They were considered to early stage in terms of there drug development potential.</gtr:impact><gtr:outcomeId>546375d18f29b1.44166217</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BIO Bio-Parnering San Diego June 23-26</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0A8E8270-43E1-43C2-B375-EDB4815F870D</gtr:id><gtr:impact>Excellent networking

Later stage discussions with two companies concerning investment and scientific collaborations.</gtr:impact><gtr:outcomeId>54637bf1dba160.28507958</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CIC biomaGUNE, San Sebastian, invited seminar speaker, 22nd  Sept 2014, Biologics with Bite</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A569F002-2741-404D-97F9-B3E0931FF9A3</gtr:id><gtr:impact>Stimulated a good level of questions and one to one meetings with senior academics in the Institute

The successful establishment of a collaboration and funding from the Spanish Government to allow Dr Mareque to visit Aberdeen for a six month sabbatical to carry our research combining shark VNAR and nanotechnologies.</gtr:impact><gtr:outcomeId>54637b26812fd3.23095878</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Darmstadt, invited seminar speaker, 9th Dec 2013 &quot;Biologics with Bite</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6CE6B2F5-108C-4574-BAD8-96E174E4EF59</gtr:id><gtr:impact>Stimulated good discussion from the audience of academics and company professionals

We now have an academic research collaboration with the University. We also have an active collaboration with Merck Serono which eventually allowed us to secure funding (partly from Merck) for a CASE PhD student.</gtr:impact><gtr:outcomeId>546378c0886380.19236070</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Biotrinity, European Biopartnering and Investment Conference, Newbury, UK, platform presentation, 16th May, Shark VNAR Biologics</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BFEB51B0-231E-4255-A7C6-2BBFFD883DBC</gtr:id><gtr:impact>The presentation stimulated interest from both companies and potential investors

One face to face meeting eventually resulted in an oncology collaboration with a mid-sized UK pharma company</gtr:impact><gtr:outcomeId>546373e0c70632.88058492</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Macduff Marine Aquarium public lecture &quot;Shark blood and how it can help humans&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E1DE8E8D-6BC0-480D-9BAE-CD8297772DED</gtr:id><gtr:impact>Talk generated a great series of interactions with primary school children, parents and teachers.

After the talk Dr Barelle was asked if she would be prepared to return the following year.</gtr:impact><gtr:outcomeId>54636f68c52419.89572537</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Bradford, Institute of Cancer Therapeutics, invited seminar speaker, 1st Nov 2013 &quot;Biologics with Bite</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AC42C2A4-656E-4672-845C-B4FB8BFFA970</gtr:id><gtr:impact>Lots of questions and a chance to meet several academic specialists in oncology for brief face to face meetings

Bradford Univesity were one of the co-ordinators of the China Mission. We were selected to be considered for the this Mission (see related engagement submission).</gtr:impact><gtr:outcomeId>546377bad01d58.28991748</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Shark Antibodies: Bigger Than Jaws - Genetic Engineering and Biotechnology News - 22 August 2013</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>217672C0-6460-4CB1-921F-6F3B3C554F7F</gtr:id><gtr:impact>Article sparked interest from other media outlets

Helped increase the profile of the project. We were asked to write a Expert Opinion Review Article because of the profile of this media article</gtr:impact><gtr:outcomeId>54637ee3c7d464.73803181</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.genengnews.com/insight-and-intelligenceand153/shark-antibodies-bigger-than-jaws/77899882/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKTI Life Sciences Mission, Tokyo, 26th Feb, Osaka, 28th Feb, Platform presentations and poster, Shark VNAR Biologics</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5260D6E6-4FE1-46D6-B4D2-95A12247B361</gtr:id><gtr:impact>This was predominantly about meeting Japanese companies that may wish to collaborate with the Aberdeen team to gain access to the VNAR platform technology or make therapeutic use of the bio-tool.

We met around 6 pharma companies during this visit and have had follow up meetings back in the UK with two of these companies. No deals in place yet.</gtr:impact><gtr:outcomeId>546372dfca52b9.23988944</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EPIC, Biopartnering Conference, London, UK, platform presentation, 6th June, Shark VNAR Biologics</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>70DDD50C-CFD2-435F-920B-559556C689A4</gtr:id><gtr:impact>Some limited interest at this meeting. Audience size and quality was small.

Made useful contacts for future networking when identifying KOLs to help with VC DD process</gtr:impact><gtr:outcomeId>546374a56937e4.98269446</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Support for a commercialisation champion to aid company formation and lead investor funding of Elasmogen (the shark VNAR asset porfolio)</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>D999D395-2449-4B3C-A248-25982F56A719</gtr:id><gtr:outcomeId>5462271df2dec6.14674307</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Innovate UK</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Innovate UK</gtr:fundingOrg><gtr:id>80EF5626-240B-49B0-9FC9-E239628BA448</gtr:id><gtr:outcomeId>56dff1a8290007.11344376</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BioMedical Catalyst</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>Innovate UK</gtr:fundingOrg><gtr:id>FD1B84CA-5A19-4294-8C19-D67887B99BF0</gtr:id><gtr:outcomeId>58c7de67a7a5e7.52950081</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SULSA MSD PhD studentship</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>ED76ED08-8CED-404A-AF76-88DB8679CF82</gtr:id><gtr:outcomeId>5463828d2da4f4.86494478</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>March 2015 Update: The most important way that our findings have been used is to provide data for the filing of patents to protect the intellectual property generated by our research and provide a valuable portfolio (drug generation platform, bio-tools and lead therapeutic molecules) which we hope we will be able to use to raise investment cash and spin out a new company.
March 2016 Update: Elasmogen Ltd a biologics drug discovery new spin-out from the UoA was successfully launched (Feb 2016) with approximately &amp;pound;850 k of equity and grant funding and a staff of 6. The focus of the company is the site-specific delivery of anti-autoimmune soloMERs (humanised candidate VNARs) specific for the treatment of inflammatory disease of the eye and gut.
March 2017: Elasmogen has continued to go from strength to strength winning a number of high profile UK sector specific awards and securing an addition &amp;pound;1.2 M in equity and grant funding. Our patent portfolio has also strengthened with an important Divisional grant in Europe and second patent granting in the US. We are also working with a number of global pharma and biotech partners</gtr:description><gtr:firstYearOfImpact>2015</gtr:firstYearOfImpact><gtr:id>3AB7FD26-C33A-4B89-A098-703B5EBC6BF1</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>54638792aab1e0.43699688</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This is an important US grant of a humanised domain derived from EO6 and described in this grant. This asset now known as NDure TM and is available for licensing. A Divisional of this patent is key to the protection of humanisation of shark VNAR domains.</gtr:description><gtr:grantRef>BB/K010905/1</gtr:grantRef><gtr:id>C40088A9-C474-44EE-960D-D9922FBD1AFE</gtr:id><gtr:impact>Elasmogen Ltd</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7fa006ce877.03894178</gtr:outcomeId><gtr:patentId>PCT/GB2013/051183</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Single domain binding molecule</gtr:title><gtr:yearProtectionGranted>2017</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This patent protects the immunisation of sharks to generate VNAR specific binders. Grants had already been achieved in Europe, Canada, Japan, Australia.</gtr:description><gtr:grantRef>BB/K010905/1</gtr:grantRef><gtr:id>50EB6DE0-D48A-4568-A822-9C926E6BA317</gtr:id><gtr:impact>Whilst no licensing income has been secured to date discussions are now on-going with potential licensees and infringers. This grant increases the likelihood of investor cash being secured into a new spin-out. It also underpins the collaborative research we carry out with other commercial partners.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>54632fed7efc79.18521375</gtr:outcomeId><gtr:patentId>US patent application 13/280 837</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Antigen Binding Domains</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This was a Divisional grant in Europe of an earlier granted patent and covers the use of shark immunisation and the selection monoclonal binders from a library of binders derived from the immunised animal using any appropriate technology. The original patent only protected the use of phage display technology. This Divisional broadens that protection considerably.</gtr:description><gtr:grantRef>BB/K010905/1</gtr:grantRef><gtr:id>DA57F28E-0A7D-4830-B870-A7657638E56D</gtr:id><gtr:impact>Spin-out company called Elasmogen Ltd</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7f8c41dd6a1.99635069</gtr:outcomeId><gtr:patentId>EP 2281837 (Div. of 1419179)</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Antigen binding domains from fish</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This patent describes VNAR domains that bind to human serum albumin and extend the half-life, in three in vivo models, of fusion proteins (therapeutic proteins) from a few hours to over two weeks.</gtr:description><gtr:grantRef>BB/K010905/1</gtr:grantRef><gtr:id>B48A398A-B65B-4895-9C11-CC93631209D5</gtr:id><gtr:impact>This patent and the domains that is describes are being used as part of commercial and academic collaborative projects. One is in oncology and the second hopes to increase half-life of an important therapeutic proteins. Both are covered by relevant agreements to protect foreground and background IP.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>54633231ea20a2.75841552</gtr:outcomeId><gtr:patentId>US 13/889,134</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Single Binding Domain Molecule</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>We have generated a candidate protein (bio-tool) that is capable when joined to other therapeutic proteins of increasing the useful time these drugs are available in the body from a few hours to over two weeks. Importantly although this bio-tool was originally derived from a shark we have humanised it in such a way to make the human body think that it is human protein and therefore will not be rejected. We have compared the success of our humanisation outcomes with other highly efficacious and commercially valuable protein drugs and we have achieved a level the same or better than these comparator molecules. We have now successfully protected through grants this molecule and the general humanisation approach when applied to shark VNAR binding domains. This IP has now progress to grant in some countries including the US.

http://www.bbsrc.ac.uk/news/impact/elasmogen-shark-proteins-for-drug-discovery/</gtr:description><gtr:exploitationPathways>This bio-tool is already being used by collaborators interested in improving the outcomes of protein based drugs that treat cancer and diseases of the blood. We are now in discussions with possible commercial partners considering taking a license to the technology.</gtr:exploitationPathways><gtr:id>2E7B7682-B2D9-4ED7-AB58-A836F8D900F4</gtr:id><gtr:outcomeId>546386afb71a15.41340034</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.elasmogen.com</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A humanised shark VNAR specific for human serum albumin that increases the half-life of partner (therapeutic) proteins (and peptides) in three in vivo PK models from a few hours to more than two weeks.</gtr:description><gtr:id>E5EC90F0-6B92-46FE-92D8-522CDC724449</gtr:id><gtr:impact>A licensable therapeutic asset. One collaboration in Oncology is using this asset to develop novel protein drug conjugate molecules. A second academic collaboration is looking to increase the half-life of therapeutic proteins in relevant animal models of disease.</gtr:impact><gtr:outcomeId>5461f304573831.54621189</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Candidate half-life extension bio-tool</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Elasmogen Ltd</gtr:companyName><gtr:description>Biologics drug discovery company focussed on the site-specific delivery of soloMER domains (humanised VNARs) for the treatment of auto-inflammatory conditions of the eye and gut.</gtr:description><gtr:id>BAD0FD42-A4E3-4E6C-A861-80743DCB4EBB</gtr:id><gtr:impact>Raised around &amp;pound;850 k to spin out in grant and equity finance in February 2016. Was second in the 2015 Converge Business Plan Challenge out of 200 technology companies that applied. First in the Life Sciences sector. Has established a number of collaborations with pharma partners. Was recognised as &amp;quot;Perfect Pitch&amp;quot; winners at BioTrinity 2016 and was shortlisted as new start spin-out of 2016 in the UK OBN awards. Was a finalist in the 2016 Innovate Showcase competition
Raised additional equity and grants totally &amp;pound;1.2 M in February 2017.

Has been used as a CASE study by BBSRC: http://www.bbsrc.ac.uk/news/impact/elasmogen-shark-proteins-for-drug-discovery/</gtr:impact><gtr:outcomeId>56dff306e09066.28334140</gtr:outcomeId><gtr:url>http://www.elasmogen.com</gtr:url><gtr:yearCompanyFormed>2016</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>C544ADC8-74E4-4FC2-B86F-BBD8E27191FB</gtr:id><gtr:title>VNARs: An Ancient and Unique Repertoire of Molecules That Deliver Small, Soluble, Stable and High Affinity Binders of Proteins</gtr:title><gtr:parentPublicationTitle>Antibodies</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1440ea237aa51d01b858370e94b7fcc"><gtr:id>d1440ea237aa51d01b858370e94b7fcc</gtr:id><gtr:otherNames>Barelle C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dfedb4e1f2d4.44421293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C05109A-9F02-4C05-8F41-3ADCA280D136</gtr:id><gtr:title>Structural insights and biomedical potential of IgNAR scaffolds from sharks.</gtr:title><gtr:parentPublicationTitle>mAbs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bf7b89e7a87fa669a8fb67dff8e13b6"><gtr:id>7bf7b89e7a87fa669a8fb67dff8e13b6</gtr:id><gtr:otherNames>Zielonka S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1942-0862</gtr:issn><gtr:outcomeId>56dfee3bdf90e8.48804238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E91C4A6F-6124-40B2-BF4A-2CF85C5278A4</gtr:id><gtr:title>Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1481dab6141b826c75be7dca4fec9bd1"><gtr:id>1481dab6141b826c75be7dca4fec9bd1</gtr:id><gtr:otherNames>Steven J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a2fcd449d37e2.20937578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58B6B95F-A2BF-4354-988E-69D460EF16C3</gtr:id><gtr:title>Novel, Anti-hTNF-a Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5346a70563676a36414a3a96e28f4f2"><gtr:id>b5346a70563676a36414a3a96e28f4f2</gtr:id><gtr:otherNames>Ubah OC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5aa8ff53d805a8.43839819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EC8898D-9981-4830-95C2-6137786E11BC</gtr:id><gtr:title>Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e18d8caae06647c3a23f3776b292a790"><gtr:id>e18d8caae06647c3a23f3776b292a790</gtr:id><gtr:otherNames>Kovaleva M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn><gtr:outcomeId>54632de4b06263.05934281</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACF25A46-34B5-4059-9ADE-854C1FA162C1</gtr:id><gtr:title>Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e18d8caae06647c3a23f3776b292a790"><gtr:id>e18d8caae06647c3a23f3776b292a790</gtr:id><gtr:otherNames>Kovaleva M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a2fcd8e81ae87.52895074</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/K010905/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>